#1 Clinical Trials Search in Europe

Ertapenem

Ertapenem is an antibiotic medication that has been the subject of several clinical trials to evaluate its effectiveness, safety, and optimal dosing in various medical conditions. These trials have focused on its use in patients with kidney problems, tuberculosis, urinary tract infections, burn injuries, and postpartum infections. The studies aim to better understand how ertapenem works in different patient populations and how to use it most effectively.

Table of Contents

What is Ertapenem?

Ertapenem, also known by its brand name Invanz, is a powerful antibiotic medication used to treat various bacterial infections[1]. It belongs to a class of antibiotics called carbapenems, which are known for their broad-spectrum activity against many types of bacteria[2]. Ertapenem is particularly useful in treating infections caused by bacteria that have become resistant to other antibiotics, making it an important tool in the fight against antibiotic-resistant infections[3].

Uses of Ertapenem

Ertapenem is prescribed to treat a variety of bacterial infections, including:

  • Complicated urinary tract infections: These are infections that affect the bladder, kidneys, or other parts of the urinary system and are more difficult to treat than simple urinary tract infections[4].
  • Complicated intra-abdominal infections: These are infections that occur within the abdomen and can be life-threatening if not treated promptly[1].
  • Acute pelvic infections: Including postpartum endometritis, which is an infection of the uterus after childbirth[5].
  • Complicated skin and soft tissue infections: These are infections of the skin and underlying tissues that are more severe or difficult to treat[1].
  • Community-acquired pneumonia: This is a type of lung infection that people can get outside of hospitals or healthcare facilities[1].

Ertapenem is particularly effective against infections caused by bacteria that produce extended-spectrum beta-lactamases (ESBL), which are enzymes that make some bacteria resistant to certain antibiotics[6].

How Ertapenem Works

Ertapenem works by interfering with the way bacteria build their cell walls. It binds to specific proteins in the bacterial cell wall, preventing the bacteria from forming a strong, protective outer layer. This ultimately leads to the death of the bacteria[2].

One of the unique features of ertapenem is its long-acting nature. It has a relatively long half-life of about 4 hours, which means it stays active in the body for a longer time compared to some other antibiotics. This allows for once-daily dosing, which can be more convenient for patients[6].

Administration and Dosage

Ertapenem is typically administered in the following ways:

  • Intravenous (IV) infusion: The most common method, where the drug is given directly into a vein over a period of 30 minutes[2].
  • Intramuscular (IM) injection: In some cases, it may be given as an injection into a large muscle[1].
  • Subcutaneous (SC) injection: Research is being conducted on administering ertapenem under the skin, especially for elderly patients with poor vein access[6].

The standard dose for adults is usually 1 gram once daily, but this can vary depending on the type and severity of the infection, as well as other patient factors[2].

Ertapenem in Special Populations

Research is ongoing to understand how ertapenem should be used in special patient populations:

  • Patients with kidney problems: Studies are being conducted to determine the appropriate dosing for patients on dialysis, as the kidneys normally play a role in eliminating the drug from the body[7].
  • Elderly patients: Research is being done to understand how ertapenem behaves in patients over 75 years old, as older adults may process medications differently[6].
  • Postpartum women: Studies are looking at how to dose ertapenem in women who have recently given birth, as pregnancy and childbirth can affect how drugs are processed in the body[5].
  • Burn patients: Research is being conducted to understand how ertapenem should be dosed in patients with severe burns, as their bodies may handle medications differently[8].

Safety and Side Effects

Like all medications, ertapenem can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea and vomiting
  • Headache
  • Injection site reactions (such as pain or swelling where the drug is given)

These side effects are usually mild and go away on their own. However, it’s important to report any persistent or severe side effects to your healthcare provider[3].

Ertapenem should not be used in patients with known allergies to carbapenem antibiotics. It’s also important to tell your doctor about all medications you’re taking, as ertapenem can interact with certain drugs[3].

Ongoing Research

Scientists continue to study ertapenem to better understand how it works in different patient populations and situations. Some areas of ongoing research include:

  • How ertapenem concentrates in different tissues of the body, such as the colon and rectum[9].
  • The use of ertapenem in treating tuberculosis, particularly in cases where the bacteria have become resistant to other antibiotics[10].
  • How to optimize dosing in patients with various medical conditions or those undergoing different types of medical treatments[7].

This ongoing research helps doctors use ertapenem more effectively and safely, ensuring that patients receive the best possible treatment for their infections.

Aspect Details
Primary Uses Treatment of complicated urinary tract infections, skin infections, intra-abdominal infections
Administration Methods Intravenous infusion (most common), subcutaneous injection (being studied)
Dosage Typically 1 gram every 24 hours, but may vary based on patient condition
Special Populations Studied Patients with kidney problems (on hemodialysis or peritoneal dialysis), elderly patients, postpartum women, burn patients
Common Side Effects Diarrhea, nausea, headache, injection site reactions
Treatment Duration Varies by condition, ranging from single dose to 14 days in clinical trials
Key Research Areas Optimal dosing in different patient populations, effectiveness against resistant bacteria, alternative administration methods

FAQ

  • What is ertapenem used for? Ertapenem is an antibiotic used to treat various infections, including complicated urinary tract infections, skin infections, and intra-abdominal infections. It's also being studied for use in patients with kidney problems, tuberculosis, and postpartum infections.
  • How is ertapenem administered? Ertapenem is typically administered intravenously (through a vein) over a period of 30 minutes. Some studies are also exploring subcutaneous administration, especially in elderly patients with poor vein access.
  • Are there any special considerations for ertapenem use in patients with kidney problems? Yes, several studies are looking at how ertapenem works in patients with kidney problems, including those on hemodialysis or peritoneal dialysis. The goal is to determine the best dosing for these patients to ensure effective treatment while avoiding potential side effects.
  • What are the potential side effects of ertapenem? Common side effects of ertapenem may include diarrhea, nausea, headache, and injection site reactions. The clinical trials are monitoring for these and other potential adverse effects to ensure the safety of the medication.
  • How long does ertapenem treatment usually last? The duration of ertapenem treatment can vary depending on the type and severity of the infection being treated. In the clinical trials, treatment durations ranged from a single dose to up to 14 days, but this can differ in real-world clinical practice.

Ongoing Clinical Trials on Ertapenem

  • Study on Preoperative Antibiotics for Patients with Acute Cholecystitis: Comparing Ertapenem, Ciprofloxacin, and Cefuroxime

    Recruiting

    1 1 1 1
    Investigated drugs:
    Finland

  • Study of Pivmecillinam and Amoxicillin/Clavulanic Acid for Treating Urinary Tract Infections in Patients with Multidrug-Resistant Bacteria

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Study Comparing Antibiotic Treatment with Placebo for Patients with Acute Appendicitis Using Ertapenem, Metronidazole, and Levofloxacin

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effects of Moxifloxacin and Drug Combination for Patients with Acute Appendicitis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Antibiotic Treatment for Uncomplicated Acute Appendicitis Using Levofloxacin, Ertapenem, and Moxifloxacin in Adult Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effectiveness of Co-Trimoxazole for Treating Ventilator-Associated Pneumonia in ICU Patients Compared to a Drug Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. This helps determine the best dosing for a medication.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Subcutaneous (SC): A method of administering medication by injecting it just under the skin.
  • Hemodialysis: A treatment for kidney failure that uses a machine to filter waste and excess fluids from the blood outside the body.
  • Peritoneal Dialysis: A type of dialysis that uses the lining of your abdomen (peritoneum) to filter waste from your blood when your kidneys can't do the job adequately.
  • Endometritis: An inflammation or irritation of the lining of the uterus, usually caused by an infection.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Extended Spectrum β-lactamase (ESBL): Enzymes produced by some bacteria that can break down and cause resistance to certain antibiotics.
  • Minimal Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Area Under the Curve (AUC): A measure used in pharmacology to describe the total drug exposure over time.

References

  1. https://clinicaltrials.gov/study/NCT00877370
  2. https://clinicaltrials.gov/study/NCT01148771
  3. https://clinicaltrials.gov/study/NCT02159859
  4. https://clinicaltrials.gov/study/NCT00379951
  5. https://clinicaltrials.gov/study/NCT01587495
  6. https://clinicaltrials.gov/study/NCT02505386
  7. https://clinicaltrials.gov/study/NCT00939952
  8. https://clinicaltrials.gov/study/NCT01497990
  9. https://clinicaltrials.gov/study/NCT00535652
  10. https://clinicaltrials.gov/study/NCT01730664